Abstract:BackgroundLeukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) is an immune inhibitory receptor that binds collagen-like domains commonly found in extracellular matrix (ECM) collagens and complement component C1q. LAIR-1 is expressed on several immune cell types including activated T cells, B cells, NK cells, dendritic cells, and macrophages. Numerous cancer types including gastric, colon, ovarian, bladder, and others, upregulate collagens which enhances tumor growth, metastases, and invasion while actively suppressing antitumor immunity. While a soluble decoy, LAIR-2, is expressed in humans and competes with LAIR-1 for binding of collagen domains, excess LAIR ligands in the tumor often result in an immune suppressive environment.MethodsHere, we report on a novel immunotherapy approach combining NC410, a novel fusion protein consisting of two LAIR-2 molecules grafted on to an IgG1 antibody backbone, capable of targeting the tumor ECM and blocking LAIR-1 signaling; and bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor β receptor II (TGF-βRII or TGF-β ”trap”) fused via a flexible linker to the C-terminus of each heavy chain of an IgG1 antibody blocking programmed death ligand 1 (anti–PD-L1).ResultsWe have demonstrated that the combination of NC410 and bintrafusp alfa more effectively controls in vivo tumor growth of the collagen rich MC38 colon and EMT6 mammary carcinomas compared to either monotherapy. We demonstrate that this potent anti-tumor immune response is propagated through the synergy of activated tumor infiltrating lymphocytes and a repolarization of myeloid cells in the tumor microenvironment. MC38 tumors treated with the combination of NC410 plus bintrafusp alfa contained higher numbers of infiltrating T cells, NK cells, and M1 polarized macrophages.ConclusionsThis study highlights the synergy of reshaping the large suppressive myeloid cell populations often present in tumors with activation of adaptive T-cell immune responses dampened by checkpoint inhibition. The results also provide the rationale for the future evaluation of this combination therapy in the clinic.

A Collagen-Binding EGFR Single-Chain Fv Antibody Fragment for the Targeted Cancer Therapy

Vascularization And Cellularization Of Collagen Scaffolds Incorporated With Two Different Collagen-Targeting Human Basic Fibroblast Growth Factors

Targeting collagen in tumor extracellular matrix as a novel targeted strategy in cancer immunotherapy

A Collagen-Binding SIRPαFc Fusion Protein for Targeted Cancer Immunotherapy.

Targeted antibody and cytokine cancer immunotherapies through collagen affinity

Molecular Mechanism of Gd@C82(OH)22 Increasing Collagen Expression: Implication for Encaging Tumor

570 Blockade of the Inhibitory Collagen Receptor LAIR-1, PD-L1, and TGF-β Promotes Anti-Tumor Activity Through T Cell Activation and Myeloid Cell Polarization

A SIRPαFc Fusion Protein Conjugated with the Collagen-Binding Domain for Targeted Immunotherapy of Non-Small Cell Lung Cancer

Sustained Endocytosis Inhibition Via Locally-Injected Drug-Eluting Hydrogel Improves ADCC-Mediated Antibody Therapy in Colorectal Cancer.

Single Chain Epidermal Growth Factor Receptor Antibody Conjugated Nanoparticles for in Vivo Tumor Targeting and Imaging

Tumor-Penetrating Peptide Fused Egfr Single-Domain Antibody Enhances Cancer Drug Penetration into 3d Multicellular Spheroids and Facilitates Effective Gastric Cancer Therapy

Localized Co-Delivery of Collagenase and Trastuzumab by Thermosensitive Hydrogels for Enhanced Antitumor Efficacy in Human Breast Xenograft.

The Mechanism of Action and Biodistribution of a Novel EGFR/VEGF Bispecific Fusion Protein That Exhibited Superior Antitumor Activities

Collagen facilitates the colorectal cancer stemness and metastasis through an integrin/PI3K/AKT/Snail signaling pathway

EGCG‐enabled Deep Tumor Penetration of Phosphatase and Acidity Dual‐responsive Nanotherapeutics for Combinatory Therapy of Breast Cancer

Extracellular Matrix Modulating Enzyme Functionalized Biomimetic Au Nanoplatform-Mediated Enhanced Tumor Penetration and Synergistic Antitumor Therapy for Pancreatic Cancer

Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment

Overcoming the Tumor Collagen Barriers: A Multistage Drug Delivery Strategy for DDR1-Mediated Resistant Colorectal Cancer Therapy

Epidermal growth factor receptors siRNA-conjugated collagen modified gold nanoparticles for targeted imaging and therapy of lung cancer

A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy

Design and Discovery of New Collagen V-Derived FGF2-Blocking Natural Peptides Inhibiting Lung Squamous Cell Carcinoma in Vitro and in Vivo.